ArticleJournal of ultrasound2025
Evaluating the clinical impact of integrating superb microvascular imaging and shear wave elastography into TI-RADS.
Article in Journal of ultrasound, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluates the diagnostic contribution of Superb Microvascular Imaging (SMI), and Shear Wave Elastography (SWE) to TI-RADS in differentiating benign and malignant thyroid nodules. MATERIALS AND
methodsThis prospective study enrolled patients scheduled for thyroid fine-needle aspiration biopsy (FNAB). Grayscale ultrasound, SMI, and SWE of the nodules were performed before FNAB. TI-RADS categories, vascularity patterns, vascularity index, and elasticity indices were recorded. Diagnostic performance was analyzed using ROC curves, logistic regression, and the DeLong test.
resultsA total of 478 thyroid nodules were analyzed, comprising 441 (92.2%) benign and 37 (7.7%) malignant cases (35 papillary and 2 medullary carcinomas). The mean age was significantly higher in the benign group (54.61 ± 11.54 years) compared to the malignant group (46.84 ± 15.38 years, p = 0.005). The most common vascularity type was type 3 (48.5% in benign and 81.1% in malignant). Malignancy rates were significantly higher in nodules with vascularity type 3 compared to type 2 (p < 0.001). ROC analysis identified an optimal SWE cut-off value of 36.9 kPa (p < 0.001), but the VI showed no significant difference (p = 0.662). The combined model consisting of TI-RADS score, SWE mean value, and vascularity distribution type demonstrated the highest diagnostic accuracy, with an AUC of 0.89.
conclusionCombination of TI-RADS, SMI, and SWE improves diagnostic accuracy in thyroid nodule assessment. Vascularity type 3 and SWE index value are strong, independent predictors of malignancy. The clinical applicability of these tools has the potential to reduce the number of unnecessary biopsies and to improve the management of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.